Valbenazine tosylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for valbenazine tosylate and what is the scope of patent protection?
Valbenazine tosylate
is the generic ingredient in three branded drugs marketed by Neurocrine, Lupin Ltd, and Zydus, and is included in four NDAs. There are twenty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Valbenazine tosylate has two hundred and twelve patent family members in thirty-three countries.
One supplier is listed for this compound. There are two tentative approvals for this compound.
Summary for valbenazine tosylate
International Patents: | 212 |
US Patents: | 22 |
Tradenames: | 3 |
Applicants: | 3 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 13 |
Patent Applications: | 38 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for valbenazine tosylate |
DailyMed Link: | valbenazine tosylate at DailyMed |
Generic filers with tentative approvals for VALBENAZINE TOSYLATE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 80MG | CAPSULE;ORAL |
⤷ Sign Up | ⤷ Sign Up | 40MG | CAPSULE;ORAL |
⤷ Sign Up | ⤷ Sign Up | EQ 60MG BASE | CAPSULE;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for valbenazine tosylate
Drug Class | Vesicular Monoamine Transporter 2 Inhibitor |
Mechanism of Action | Vesicular Monoamine Transporter 2 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for valbenazine tosylate
Paragraph IV (Patent) Challenges for VALBENAZINE TOSYLATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
INGREZZA | Capsules | valbenazine tosylate | 60 mg | 209241 | 1 | 2022-02-14 |
INGREZZA | Capsules | valbenazine tosylate | 40 mg and 80 mg | 209241 | 4 | 2021-04-12 |
US Patents and Regulatory Information for valbenazine tosylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurocrine | INGREZZA SPRINKLE | valbenazine tosylate | CAPSULE;ORAL | 218390-002 | Apr 30, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Neurocrine | INGREZZA SPRINKLE | valbenazine tosylate | CAPSULE;ORAL | 218390-001 | Apr 30, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Neurocrine | INGREZZA SPRINKLE | valbenazine tosylate | CAPSULE;ORAL | 218390-002 | Apr 30, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for valbenazine tosylate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2022544711 | 特定のVMAT2阻害剤を重度腎障害の患者に投与するための方法 | ⤷ Sign Up |
Australia | 2017395700 | Methods for the administration of certain VMAT2 inhibitors | ⤷ Sign Up |
Serbia | 65154 | SOLI VALBENAZIN DIHIDROHLORIDA I NJIHOVI POLIMORFI (VALBENAZINE DIHYDROCHLORIDE SALTS AND POLYMORPHS THEREOF) | ⤷ Sign Up |
Canada | 3149033 | PROCEDES D'ADMINISTRATION DE CERTAINS INHIBITEURS DE VMAT2 A DES PATIENTS PRESENTANT UNE INSUFFISANCE RENALE GRAVE (METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.